查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1785351

连网药物输送设备市场－全球产业规模、份额、趋势、机会及预测，依产品类型、给药途径、应用、地区及竞争细分，2020-2030 年预测

Connected Drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type, By Route of Administration, By Application, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年，全球连网药物输送设备市场规模达64.5亿美元，预计2030年将达151.5亿美元，复合年增长率为15.25%。全球连网药物输送设备市场正在经历重大变革，其驱动力包括先进数位技术的整合、医疗服务模式的转变，以及对个人化、结果导向医疗的日益重视。这些新一代药物传输系统配备嵌入式感测器、蓝牙连接、配套行动应用程式和云端分析功能，旨在增强患者服药依从性，提供切实可行的健康洞察，并改善长期治疗效果，尤其适用于慢性病管理。

市场概览
预测期 2026-2030
2024年市场规模 64.5亿美元
2030年市场规模 151.5亿美元
2025-2030 年复合年增长率 15.25%
成长最快的领域 肠外
最大的市场 北美洲

该市场处于医疗创新、数位转型和医药进步的交汇点，发展势头强劲。包括生物製药公司、医疗科技公司、支付方和医疗服务提供者在内的整个生态系统的利益相关者正在积极投资互联治疗平台，这些平台支援远端监控、自动化依从性追踪并实现即时患者互动。随着监管框架的日趋成熟和数位医疗报销的更加结构化，该市场将迅速扩张，尤其是在慢性病负担日益加重、数位化基础设施日益完善的地区。互联药物输送领域已不再是小众市场，而是正在成为未来精准医疗和去中心化医疗服务交付的策略支柱。

关键市场驱动因素

需要长期服药的慢性病盛行率上升

主要市场挑战

设备成本高且报销支援有限

主要市场趋势

将人工智慧 (AI) 和高级分析整合到互联设备中

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：连网药物输送设备市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依产品类型（独立组件和软体、整合设备）
    • 依给药途径（肠胃外、吸入）
    • 依应用（气喘、慢性阻塞性肺病、糖尿病管理、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美连网药物传输设备市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲联网药物输送设备市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第八章：亚太联网药物传输设备市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：南美联网药物输送设备市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东和非洲联网药物输送设备市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章：全球连网药物输送设备市场：SWOT 分析

第 14 章：竞争格局

  • Teva Pharmaceutical Industries Ltd.
  • Novo Nordisk A/S
  • Phillips Medisize
  • Medtronic Plc.
  • Adherium Limited
  • Tandem Diabetes Care, Inc.
  • Biocorp Life Sciences Pvt. Ltd
  • Resmed Corp
  • Ypsomed AG
  • AptarGroup, Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 7438

Global Connected Drug Delivery Devices market was valued at USD 6.45 Billion in 2024 and is expected to reach USD 15.15 Billion by 2030 with a CAGR of 15.25%. The Global Connected Drug Delivery Devices Market is undergoing a significant evolution, shaped by the integration of advanced digital technologies, shifting healthcare delivery models, and the rising emphasis on personalized, outcomes-driven care. These next-generation drug delivery systems equipped with embedded sensors, Bluetooth connectivity, companion mobile apps, and cloud-based analytics are purpose-built to enhance medication adherence, deliver actionable health insights, and improve long-term treatment outcomes, particularly for chronic disease management.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.45 Billion
Market Size 2030USD 15.15 Billion
CAGR 2025-203015.25%
Fastest Growing SegmentParenteral
Largest MarketNorth America

Positioned at the nexus of healthcare innovation, digital transformation, and pharmaceutical advancement, this market is gaining strong momentum. Stakeholders across the ecosystem including biopharma companies, medtech firms, payers, and providers are actively investing in connected therapeutic platforms that support remote monitoring, automate adherence tracking, and enable real-time patient engagement. As regulatory frameworks mature and digital health reimbursement becomes more structured, the market is set to scale rapidly, especially in regions with growing chronic disease burdens and increasing digital infrastructure. The connected drug delivery landscape is no longer a niche it's emerging as a strategic pillar in the future of precision medicine and decentralized care delivery.

Key Market Drivers

Rising Prevalence of Chronic Diseases Requiring Long-Term Medication

The escalating global burden of chronic diseases is a primary catalyst fueling the growth of the Global Connected Drug Delivery Devices Market. Chronic diseases such as cardiovascular disorders, cancer, diabetes, and chronic respiratory illnesses now represent the primary drivers of mortality and long-term disability worldwide. These conditions account for approximately 75% of all global deaths, underscoring their disproportionate impact on both public health and economic productivity. Chronic diseases account for nearly three-quarters of global deaths and continue to rise due to aging populations, sedentary lifestyles, urbanization, and poor dietary habits.

Over 537 million adults are currently living with diabetes, a number expected to exceed 783 million by 2045. According to the Global Initiative for Asthma (GINA), asthma remains one of the most widespread chronic non-communicable diseases, impacting more than 260 million individuals globally. It is a major contributor to global morbidity and is linked to over 450,000 deaths annually. The high incidence and mortality associated with asthma reflect a persistent gap in disease control, adherence, and access to effective management tools particularly in underserved regions. This highlights a growing market opportunity for connected respiratory drug delivery solutions that can improve treatment precision, monitor patient adherence in real time, and reduce preventable asthma-related complications. These diseases often require daily or weekly medication regimens involving injectables, inhalers, or complex drug delivery protocols. This rapidly growing patient pool directly increases demand for connected devices that ensure accurate dosing, adherence tracking, and ongoing patient support.

Medication non-adherence is a major concern in chronic disease management, leading to worsening health outcomes, increased hospitalizations, and higher healthcare costs. Research consistently indicates that 40% to 60% of patients managing chronic conditions exhibit poor medication adherence, frequently skipping doses, mismanaging dosage schedules, or discontinuing treatment prematurely. Connected drug delivery devices help solve this challenge by: Providing automated reminders and alerts through mobile apps. Tracking real-time usage and sending adherence data to healthcare providers. Enabling patient engagement through visual feedback, usage history, and digital coaching. By improving adherence, these devices not only enhance clinical outcomes but also align with the priorities of healthcare payers and providers who are focused on value-based care delivery. Patients with chronic conditions often require long-term, consistent drug administration that can be managed at home without the need for frequent clinic visits. Connected drug delivery devices support this transition by enabling: Self-injection or inhalation with minimal training, even for biologics and specialty medications. Real-time feedback to ensure correct usage, minimizing the risk of administration errors. Remote data sharing with physicians, allowing for continuous therapy optimization and proactive intervention. This functionality is especially crucial for diseases like rheumatoid arthritis, multiple sclerosis, and hormone disorders, where biologics and specialty injectables are becoming the standard of care.

Key Market Challenges

High Cost of Devices and Limited Reimbursement Support

One of the most significant barriers to market expansion is the high upfront cost associated with connected drug delivery devices, especially compared to traditional drug administration methods. These devices often incorporate advanced features such as Bluetooth connectivity, integrated sensors, and cloud-based data transmission all of which increase production costs.

For healthcare providers and payers, especially in price-sensitive markets, justifying the added cost becomes challenging without a clear and quantifiable return on investment (ROI). Reimbursement frameworks remain fragmented and inconsistent across regions. In many countries, connected devices are not fully covered under public or private insurance plans, limiting patient accessibility particularly in low- and middle-income economies. Additionally, the cost of accompanying digital infrastructure (such as mobile apps, cloud platforms, and device integration with EHRs) can further complicate adoption. Until reimbursement models evolve to recognize the long-term cost savings of improved adherence and reduced hospitalizations, affordability will continue to be a limiting factor.

Key Market Trends

Integration of Artificial Intelligence (AI) and Advanced Analytics into Connected Devices

One of the most significant trends shaping the future of connected drug delivery devices is the integration of AI and real-time analytics. Modern devices are evolving from passive tracking tools into intelligent therapeutic systems capable of learning from user data and dynamically optimizing treatment regimens.

Predictive dosing algorithms can now analyze historical adherence data, biometrics (e.g., blood glucose levels), and behavioral trends to fine-tune dosage recommendations in real time. AI-driven insights allow early identification of non-compliance, adverse events, or therapy deviations, which helps healthcare providers intervene proactively. This trend is particularly impactful in chronic disease management such as diabetes and asthma, where continuous optimization of therapy enhances patient outcomes while reducing hospitalization costs. Pharmaceutical companies are increasingly partnering with digital health firms to develop smart therapeutics, combining connected devices with data-driven platforms, creating a seamless patient-provider feedback loop.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Novo Nordisk A/S
  • Phillips Medisize
  • Medtronic Plc.
  • Adherium Limited
  • Tandem Diabetes Care, Inc.
  • Biocorp Life Sciences Pvt. Ltd
  • Resmed Corp
  • Ypsomed AG
  • AptarGroup, Inc

Report Scope:

In this report, the Global Connected Drug Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Connected Drug Delivery Devices Market, By Product Type:

  • Standalone Components & Software
  • Integrated Devices

Connected Drug Delivery Devices Market, By Route of Administration:

  • Parenteral
  • Inhalational

Connected Drug Delivery Devices Market, By Application:

  • Asthma
  • COPD
  • Diabetes Management
  • Others

Connected Drug Delivery Devices Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Connected Drug Delivery Devices Market.

Available Customizations:

Global Connected Drug Delivery Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Connected Drug Delivery Devices Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Standalone Components & Software, Integrated Devices)
    • 5.2.2. By Route of Administration (Parenteral, Inhalational)
    • 5.2.3. By Application (Asthma, COPD, Diabetes Management, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Connected Drug Delivery Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Connected Drug Delivery Devices Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Connected Drug Delivery Devices Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Connected Drug Delivery Devices Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Application

7. Europe Connected Drug Delivery Devices Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Connected Drug Delivery Devices Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Application
    • 7.3.2. United Kingdom Connected Drug Delivery Devices Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Application
    • 7.3.3. Italy Connected Drug Delivery Devices Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Application
    • 7.3.4. France Connected Drug Delivery Devices Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Connected Drug Delivery Devices Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Application

8. Asia-Pacific Connected Drug Delivery Devices Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Connected Drug Delivery Devices Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Application
    • 8.3.2. India Connected Drug Delivery Devices Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Connected Drug Delivery Devices Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Connected Drug Delivery Devices Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Connected Drug Delivery Devices Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Application

9. South America Connected Drug Delivery Devices Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Connected Drug Delivery Devices Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Application
    • 9.3.2. Argentina Connected Drug Delivery Devices Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Application
    • 9.3.3. Colombia Connected Drug Delivery Devices Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Application

10. Middle East and Africa Connected Drug Delivery Devices Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Connected Drug Delivery Devices Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Application
    • 10.3.2. Saudi Arabia Connected Drug Delivery Devices Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Application
    • 10.3.3. UAE Connected Drug Delivery Devices Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Connected Drug Delivery Devices Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Teva Pharmaceutical Industries Ltd.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Novo Nordisk A/S
  • 14.3. Phillips Medisize
  • 14.4. Medtronic Plc.
  • 14.5. Adherium Limited
  • 14.6. Tandem Diabetes Care, Inc.
  • 14.7. Biocorp Life Sciences Pvt. Ltd
  • 14.8. Resmed Corp
  • 14.9. Ypsomed AG
  • 14.10.AptarGroup, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer